What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.